Mounjaro weight loss medication narrows breast cancer tumors in mice

In a revealing preclinical study, the firing of the weight loss medication – already known to combat obesity and diabetes – has slowed down the growth of breast cancer tumors in obese mice.

The researchers discovered that when the mice lost fats, their tumors also shrunk, suggesting a direct link between weight loss and reduction in cancer progression.

The promising obesity medication limits breast cancer in mice

A recent study presented at Endo 2025, the annual meeting of Endocrine Society in San Francisco, California, revealed that shooting, a drug approved for type 2 diabetes under the Mounjaro brand and for weight loss as Zepbound, slowed down the growth of breast cancer related to an obesity model.

“Obesity is a significant risk factor for breast cancer, and although it is very preliminary data, our studies in mice suggest that these new anti-obeezing drugs can be a means of reducing the risk of breast cancer associated with obesity or improving results,” said the author of the Amanda Kucinskas study, BS, A PH.D. Erin Giles and singer of Kanakadurga at the University of Michigan in Ann Arbor, Michigan.

Challenges of traditional weight loss for cancer prevention

Scientists have long since known that obesity can lead to lower results for people with breast cancer, while weight loss has been associated with better forecasts. However, the realization and maintenance of weight loss through conventional methods are difficult for many people.

To explore alternatives, Kucinskas and his team turned to shooting. This drug belongs to a new class of drugs that activate both GLP-1 (glucagon type peptide) and GIP (insulinotropic polypeptide dependent on glucose), which are involved in the regulation of blood sugar and appetite. Researchers aimed to determine whether this medication could also slow the progression of obesity breast cancer.

Within the design of the mouse study

This mouse study included 16 mice. C57BL / 6 9 -week mouses received a 40% fat diet and hosted in a hot environment to induce obesity. At 32 weeks, mice with obesity were randomly assigned to tizepatid injections or a placebo every two days for 16 weeks. The tumor volumes have been measured twice a week.

Researchers have found that the anti-obesity medication reduced body weight and body fat by around 20% in mice, similar to the amount of weight loss obtained by women on this medication. They found that this was mainly due to a loss of fat mass, with a reduction in the weight of adipose deposits compared to witnesses.

Corporal weight correlation with tumor growth

The anti-obesity medication has also reduced the tumor volume compared to witnesses. At the end of the study, the researchers found that the tumor volume was significantly correlated with the body weight, the total adipose mass and the amount of fat stored in the liver.

“Although they are very preliminary results, they suggest that this new anti-obeezing medication can also have a beneficial impact on breast cancer results,” Kucinskas said.

Current studies are underway in collaboration with the laboratory of Dr Steve Hursting at the University of North Carolina in Chapel Hill to separate weight loss from the specific effects of the shooting tumor.

Meeting: Endo 2025

Never miss a breakthrough: join the Scitechdaily newsletter.